Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements
In tackling reverse payments, should a different policy tact might be called for; one that shifts emphasis from determining whether or not reverse payments should be per se illegal to working with the incentives that firms already face.
When requesting a correction, please mention this item's handle: RePEc:cpi:cpijrn:5.2.2009:i=5339. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Lindsay McSweeney)
If references are entirely missing, you can add them using this form.